Table 1.
Characteristics of the study population.
| N = 68 | ||
|---|---|---|
| Age, years, median (IQR) | 63.0 | (58.0–70.5) |
| Male gender | 43 | (63.2) |
| Body mass index, kg/m2, median (IQR) (n = 36) | 24.8 | (21.6–30.3) |
| History of hematologic malignancies † | 5 | (7.4) |
| Monoclonal gammopathy of undetermined significance | 1 | (1.5) |
| Myelodysplastic syndrome | 2 | (2.9) |
| Multiple myeloma | 1 | (1.5) |
| Diffuse large B cell lymphoma in remission | 1 | (1.5) |
| History of cancer | 6 | (8.8) |
| History of autoimmune disease (n = 66) | 7 | (10.3) |
| Cured ITP | 2 | (3.0) |
| Crohn’s disease | 1 | (1.5) |
| Hypothyroidism | 2 | (3.0) |
| Sarcoidosis | 1 | (1.5) |
| Overlap Sjogren’s syndrome/Behçet’s disease | 1 | (1.5) |
| ICI-treated cancer type | ||
| Lung cancer | 32 | (47.1) |
| Melanoma | 22 | (32.4) |
| Renal cell carcinoma | 4 | (5.8) |
| Head and neck squamous cell carcinoma | 3 | (4.4) |
| Urinary cancer | 2 | (2.9) |
| Other | 5 | (7.4) |
| ICI as first-line treatment (n = 53) | 25 | (47.2) |
| ICI | ||
| Anti-PD-1 | 55 | (80.9) |
| Pembrolizumab | 32 | (47.1) |
| Nivolumab | 23 | (33.8) |
| Anti-PD-1 + anti-CTLA-4 (nivolumab and ipilimumab) | 6 | (8.8) |
| Anti-PD-L1 | 5 | (7.4) |
| Atezolizumab | 3 | (4.4) |
| Durvalumab | 1 | (1.5) |
| Avelumab | 1 | (1.5) |
| Anti-CTLA-4 (ipilimumab) | 2 | (2.9) |
| Concomitant chemotherapy (n = 67) | 5 | (7.4) |
| Death from immune-related cytopenia | 3 | (4.4) |
| ICI resumption after immune-related cytopenia ‡ | 10 | (14.7) |
Data are expressed as n (%) unless otherwise stated. † Other than ICI indication. ‡ ICI discontinuation for a period at least equal to twice the duration of a cycle, with subsequent ICI restarting. CTLA-4: Cytotoxic T-lymphocyte antigen-4, ICI: Immune checkpoint inhibitor, IQR: Interquartile range, ITP: Immune thrombocytopenic purpura, PD-1: Programmed cell death 1, PD-L1: Programmed cell death ligand.